Swedish Orphan Biovitrum AB (B6E.BE)
| Previous close | 26.88 |
| Open | 26.80 |
| Bid | 26.66 x 0 |
| Ask | 26.92 x 0 |
| Day's range | 26.80 - 26.80 |
| 52-week range | 17.66 - 29.22 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Sobi has completed issues of class C shares
The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 14 May 2024 resolved on directed issues of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued class C shares through an acquisition offer directed to all owners of class C shares in Sobi. The Board of Directors of Sobi has, as previously communicated, on 15 July resolved to, conditional upon subscription and payment from Svenska Handelsbanken AB, r
- PR Newswire
NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A
Sobi® today announced the publication of full results from the Phase 3 XTEND-Kids study in The New England Journal of Medicine (NEJM) confirming the safety and efficacy profile of ALTUVOCT® (efanesoctocog alfa), in children younger than 12 years old with severe haemophilia A. The study demonstrated that fixed-dose once-weekly prophylaxis with ALTUVOCT, a new class of high-sustained factor VIII therapy, provided highly effective bleed protection in children.
- PR Newswire
Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
Second Quarter 2024
